Ataxin 1 (ATXN1) Antibody

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known.

Target	Ataxin 1 (ATXN1)
Clonality	Polyclonal
Reactivity	Human
Tested Applications	ELISA, WB, IF/ICC
Host	Rabbit
Recommended dilutions	WB: 1/2000, IF/ICC: 1/10 - 1/50. Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Immunogen	KLH-conjugated synthetic peptide between 754-781 amino acids from human ATXN1.
Isotype	IgG
Form	Liquid
Purification	Purified through a protein A column, followed by peptide affinity purification.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
UniProt Primary AC	P54253 (UniProt, ExPASy)
UniProt Secondary AC	Q17S02, Q9UJG2, Q9Y4J1
UniProt Entry Name	ATX1_HUMAN
KEGG	hsa:6310
String	9606.ENSP00000244769
Molecular Weight	Calculated MW: 86.9 kDa
Buffer	PBS containing 0.09% sodium azide.
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.

Research Articles on Ataxin 1 (ATXN1)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue